Lineage Cell Therapeutics Analyst Ratings
Lineage Cell Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 07/25/2023 | 325.53% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 07/24/2023 | 396.45% | HC Wainwright & Co. | $7 → $7 | Reiterates | Buy → Buy |
| 05/12/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | Buy → Buy |
| 04/26/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 03/10/2023 | 396.45% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 11/02/2022 | 254.61% | Baird | → $5 | Initiates Coverage On | → Outperform |
| 06/14/2022 | 183.69% | B. Riley Securities | → $4 | Initiates Coverage On | → Buy |
| 08/19/2021 | 467.38% | Noble Capital Markets | → $8 | Initiates Coverage On | → Outperform |
| 03/31/2021 | 325.53% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 09/17/2020 | — | Noble Capital Markets | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月11日 | 396.45% | HC Wainwright公司 | →$7 | 重申 | 購買→購買 |
| 07/25/2023 | 325.53% | 康託·菲茨傑拉德 | →$6 | 重申 | 超重→超重 |
| 07/24/2023 | 396.45% | HC Wainwright公司 | $7→$7 | 重申 | 購買→購買 |
| 2023年05月12日 | 396.45% | HC Wainwright公司 | →$7 | 重申 | 購買→購買 |
| 04/26/2023 | 396.45% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 03/10/2023 | 396.45% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 11/02/2022 | 254.61% | 貝爾德 | →$5 | 開始承保 | →跑贏大盤 |
| 2022/06/14 | 183.69% | B.萊利證券 | →$4 | 開始承保 | →購買 |
| 2021/08/19 | 467.38% | 來寶資本市場 | →$8 | 開始承保 | →跑贏大盤 |
| 03/31/2021 | 325.53% | 康託·菲茨傑拉德 | →$6 | 開始承保 | →超重 |
| 09/17/2020 | - | 來寶資本市場 | 開始承保 | →跑贏大盤 |
What is the target price for Lineage Cell Therapeutics (LCTX)?
LCTX的目標價格是多少？
The latest price target for Lineage Cell Therapeutics (AMEX: LCTX) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $7.00 expecting LCTX to rise to within 12 months (a possible 396.45% upside). 7 analyst firms have reported ratings in the last year.
2023年8月11日，HC Wainwright&Co.報道了Lineage細胞治療公司(美國證券交易所代碼：LCTX)的最新目標價。這家分析公司將目標價定為7美元，預計LCTX將在12個月內上漲至(可能上漲396.45%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Lineage Cell Therapeutics (LCTX)?
譜系細胞治療公司(LCTX)的最新分析師評級是什麼？
The latest analyst rating for Lineage Cell Therapeutics (AMEX: LCTX) was provided by HC Wainwright & Co., and Lineage Cell Therapeutics reiterated their buy rating.
對Lineage Cell Treateutics(美國證券交易所代碼：LCTX)的最新分析師評級由HC Wainwright&Co.提供，Lineage Cell Treateutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Lineage Cell Therapeutics (LCTX)?
LCTX(LCTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lineage Cell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lineage Cell Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公共財務報表，與Lineage Cell Treateutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Lineage細胞治療公司的上一次評級是在2023年8月11日提交的，所以你應該預計下一次評級將在2024年8月11日左右提供。
Is the Analyst Rating Lineage Cell Therapeutics (LCTX) correct?
分析師對LCTX的評級正確嗎？
While ratings are subjective and will change, the latest Lineage Cell Therapeutics (LCTX) rating was a reiterated with a price target of $0.00 to $7.00. The current price Lineage Cell Therapeutics (LCTX) is trading at is $1.41, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的LCTX評級被重申，目標價在0.00美元至7.00美元之間。目前LCTX的交易價格為1.41美元，在分析師的預測範圍內。